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T he clinical consequences of peripheral arterial disease (PAD) include pain on walking (claudication), pain at rest, and loss of tissue integrity in the distal ischemic limbs. Recent progress in molecular biology has led to the development of gene therapy as a new strategy to treat a variety of cardiovascular diseases using angiogenic growth factors, such as vascular endothelial growth factor (VEGF). [1] [2] [3] However, recent reports have documented the disadvantage of VEGF, such as edema formation, 1, 2, 4 and recent studies have demonstrated that VEGF121 did not show improvement in clinical end points. 5 In contrast, although phase II nonviral fibroblast growth factor-1 clinical trial revealed a significant decrease in the amputation rate, 6 large-scale phase III trial failed to show its efficacy. 7 Our previous reports demonstrated that intramuscular gene transfer of naked plasmid DNA containing the sequence encoding human hepatocyte growth factor (HGF), a potent angiogenic growth factor, [8] [9] [10] [11] [12] [13] [14] [15] in patients with critical limb ischemia (CLI) resulted in a significant increase in anklebranchial pressure index (ABI) and improved clinical symptoms, such as ischemic ulcer at 2 months after transfection. 16, 17 In addition, 3 randomized placebo control studies (1 phase III trial in Japan and 2 phase II trials in the United States) demonstrated the healing of ulcer, decrease in rest pain, increase in transcutaneous oxygen tension, or toe pressure at 2 or 6 months after the treatment. [18] [19] [20] These clinical trials including ours revealed clinical therapeutic values of HGF gene therapy to treat CLI. Of particular interests, different from VEGF, HGF gene therapy did not show edema as side effects. However, previous studies only showed short-term efficacy of HGF gene therapy but not long-term efficacy, amputation rate, and mortality. Thus, we sought to evaluate the long-term safety and clinical effects of direct intramuscular gene transfer of naked human HGF plasmid DNA on ABI, ulcer, and rest pain as functional end points, and amputation and death rate as hard end points up to 2 years after gene therapy in 22 no-option patients with severe PAD refractory to maximal medical therapy and not amenable to conventional revascularization. The present study documented the continuous improvement in clinical symptoms, such as the healing of ulcers. Despite
Materials and Methods

Clinical Trial Design
This study was conducted as a phase I/IIa investigator-initiated clinical trial, as previously described. 16, 17 Part of the information included in this article has been published in the previous reports. 16, 17 Briefly, the pVAX1 plasmid vector (Invitrogen Corporation, Carlsbad, CA) was selected for HGF construct. To minimize the possibility of chromosomal integration, insertional mutagenesis through the activation of oncogenes, or inactivation of tumor suppressor genes, all sequences with possible homology to the human genome have been removed from the pVAX1 DNA, along with any sequence not necessary for replication in Escherichia coli or for expression of recombinant protein in mammalian cells. The pVAX1 HGF plasmid consists of a cDNA fragment of human HGF inserted into the pVAX1 vector.
In this single-center prospective, open-label study, patients were enrolled if they (1) had chronic CLI, including rest pain and a nonhealing ischemic ulcer, or had severe intermittent claudication with maximum walking distance <200 m for a minimum of 4 weeks; (2) had been resistant to conventional drug therapy for >4 weeks; (3) were not candidates for surgical or percutaneous revascularization based on usual standards of practice; (4) did not have previous or current neoplasms; and (5) did not have severe retinopathy, as documented previously. 16, 17 Objective documentation of ischemia, including resting ABI of >0.6 in the affected limb on 2 consecutive examinations performed 1 week apart, was necessary. Patients were observed for 4 weeks under conventional drug therapy to confirm that their clinical symptoms and objective parameters were not improved. The study was approved by the Ministry of Health, Labor, and Welfare, and Ministry of Education, Culture, Sports, Science, and Technology. Twenty-two limbs of 17 patients (13 men and 4 women; 59.6±12.0 years) with arteriosclerosis obliterans (ASO; n=14) or Buerger disease (thromboangitis obliterans [TAO]; n=8) staged as Fontaine IIb, III, or IV underwent direct intramuscular gene transfer of naked plasmid DNA encoding HGF. The characteristics of the patients are shown in Table 1 and in a previous article. 17 In 4 patients, plasmid was administrated to bilateral legs one-by-one at an interval >3 months. One patient was treated bilaterally at the same time.
Intramuscular Injection of Naked Plasmid DNA Encoding Human HGF
Each patient received an intramuscular injection of naked plasmid HGF DNA, as described previously. 16, 17 This study was divided into 2 stages. As stage 1, for the initial 6 patients with Fontaine stage III or IV, a test intramuscular injection of a small dose (test injection) (0.4 mg plasmid DNA) was performed to examine acute or subacute allergy to plasmid DNA. After confirmation of no allergic reaction or anaphylaxis, 2 mg of naked HGF plasmid DNA was intramuscularly injected 2 weeks after test injection into the calf or distal thigh muscles of the ischemic limb by direct intramuscular injection under ultrasonic guidance. The injection sites of plasmid DNA are described in our previous preliminary report. 17 Four weeks after the initial injection, a second injection (2 mg) was similarly administered, giving a total dose of 4 mg plasmid DNA per patient. Results of this study up to 6 months were previously published. 17 As stage 2, 16 limbs of 12 patients with Fontaine stage IIb, III, or IV were intramuscularly injected with a therapeutic dose (2 mg/4 sites or 4 mg/8 sites) of naked HGF plasmid DNA. The doses of HGF plasmid were randomly allocated using an envelope method. HGF plasmid DNA (0.5 mg) was diluted in sterile saline solution up to 3 mL, and 4 or 8 aliquots (total 2 or 4 mg/12 or 24 mL) were administered as stage 1. Four or 8 injection sites were selected arbitrarily, according to the angiographic findings and the available muscle mass. Four weeks after the initial injection, the second injection was similarly administered, giving a total dose of 4 or 8 mg plasmid DNA per patient.
Patient Follow-Up and Assessment
Briefly, patients were followed by physical examination (including change in ischemic ulcers), blood analysis, visual analog scale pain scale (VAS), and measurements of ABI weekly during the first 12 weeks, every other week for the next 8 weeks, monthly for the next 12 weeks, and then every 3 months up to 2 years after the first injection of plasmid DNA. ABI was measured using plethysmographic wave or Doppler wave system, IMEX (Getz Bros. Co). Maximum walking distance was measured at baseline, 1, 2, 3, and 24 months using treadmill at 2.4 km/h with 5% incline. During the study period, the development of malignant tumors and progression of retinopathy were carefully investigated by various examinations.
Statistical Analysis
All values are expressed as mean±SD. To compare the clinical parameters (ABI, ulcer size, VAS, and maximum walking distance) between baseline and each time point, the Dunnet test was used. To test the long-term increasing or decreasing tendency of these clinical parameters, the regression coefficient of the time course was calculated. To assess the time-dependent change in these parameters Case Nos. 5 and 7, 9 and 16 , 11 and 18, and 19 and 22 represent same patients, respectively. In those 4 patients, plasmid was administrated to bilateral legs one-by-one at an interval >3 months. Case No. 20 and 21 also represent the same patient, who was treated bilaterally at the same time.
between 2 groups, such as ASO and TAO, or CLI and intermittent claudication, the regression coefficient of time course was compared using ANCOVA. P<0.05 was considered statistically significant. All tests were 2-tailed. To avoid any bias, an evaluation committee independent from the trial investigators checked all the data. The JMP statistical software was used for calculations.
Results
Long-Term Efficacy of HGF Gene Therapy
In this study, we evaluated ABI as a functional end point and resting pain, as assessed by VAS or the size of ischemic ulcer, as a clinical end point. As previously reported, 17 ABI significantly increased from 0.46±0.08 (n=17) at baseline (before administration) to 0.59±0.13 (P=0.0135; n=17) at 8 weeks after injection ( Figure 1A ). Even at 2 years after gene therapy, ABI still increased significantly (0.61±0.13; P=0.0053; n=14), whereas the peak increase in ABI was observed at 6 months after treatment (0.65±0.15). There was no significant time dependency in ABI increase (regression coefficient, 0.00359; P=0.051). We also analyzed the results of ABI according to Fontaine stage III-IV (CLI) and stage II ( intermittent claudication). There was no significant difference in the improvement of ABI between the 2 groups (P=0.1620) ( Figure I in the online-only Data Supplement). When an increase in ABI of >0.1 was assumed to be an improvement, according to the standard of Rutherford, 11 of 17 patients (65%) showed a positive response at 2 months after transfection ( Table 2 ). The efficacy rate of ABI after 2 years reached 79% (11 of 14 patients). These results demonstrated that functional improvement in blood flow induced by HGF still continued up to 2 years after transfection, despite the short duration of gene expression.
To evaluate the effects of HGF gene therapy on clinical symptoms, we evaluated rest pain using visual analog scale, as a standard method for evaluation of pain. As shown in Figure 1B , rest pain had significantly improved at 2 months after transfection (P=0.0042). Importantly, rest pain gradually improved in a time-dependent manner (regression coefficient, −0.184; P<0.0001). Rest pain reduced from 5.92±1.67 (n=13) at baseline to 0.39±0.99 (n=9) at 2 years after transfection. In this trial, 9 of 9 patients (100%) demonstrated improvement in rest pain over 2 cm at 2 years after transfection and in 8 of 13 patients (62%) at 2 months after transfection ( Table 2 ). In this trial, a total of 25 ischemic ulcers were found in 11 patients at baseline. The size of the largest ulcer had significantly reduced from 3.08±1.53 (n=11) at baseline to 0.61±1.27 (n=10) at 2 years ( Figure 1C ). Consistent with the gradual improvement in rest pain, ischemic ulcer also significantly reduced in a time-dependent manner (regression coefficient, −0.0926; P=0.0004; Figure 1C ). At 2 years after transfection, the reduction in ischemic ulcer reached 0.61±1.27 (n=10). Considering an improvement in ischemic ulcers by >25% to be evaluated as positive, 18 of 25 ulcers (72%) had improved at 2 months after transfection. It is noteworthy that at 2 years after transfection, 17 of 18 ulcers (94%) reduced by >25%. As shown in Figure 1C , the largest ischemic ulcer diameter also reduced after transfection. Seven of 11 patients (efficacy rate 64%) demonstrated an improvement in the largest ischemic ulcer diameter by >25% at 2 months and 9 of 10 patients (efficacy rate 90%) at 2 years (Table 2) . At 2 months, one of 11 ulcers completely healed. Typical examples of the changes in ischemic ulcers in patients with ASO and Buerger disease are shown in Figure 2 . Two years after transfection, 7 of the 11 patients with ulcers achieved complete healing (Table 3 ). In this trial, 7 patients with Fontaine Iib stage were also tested. Peak walking time had significantly increased at 2 and 3 months after second transfection ( Figure 1D) ; however, this effect was diminished at 2 years. In addition, we compared the time-dependent changes in patients with ASO and TAO, because these 2 groups have different characteristics in pathophysiology and clinical course. Both groups showed an improvement in ABI, ulcer size, and VAS ( Figure II in the online-only Data Supplement). However, there was no significant difference in the tendency between the 2 groups. We also evaluated the transition of the Fontaine stage. As shown in Table 4 , 5 of 11 patients with ABI indicates ankle-branchial pressure index. Efficacy rates are indicated as effective cases/total cases (%). An ABI increase by >0.1, a visual analog scalepain scale reduction by >2 cm, and an ulcer diameter reduction by >25% were defined as effective cases. 2M, 6M, 12M, 24M indicate 2, 6, 12, and 24 months, respectively, after the second injection.
stage IV improved to stage IIb at 2 years. Similarly, 1 of 4 patients with stage III improved to stage IIb.
Safety Evaluation
We also evaluated the safety of HGF gene therapy up to 2 years. Especially, we focused on the incidence of angiogenesisrelated disease, such as tumor, and other severe complications. The initial trial up to 6 months documented no evidence of the allergic reaction related to plasmid DNA. 17 Similarly, 2-year follow-up also documented that none of the patients showed an allergic or anaphylactic reaction. No serious adverse events related to gene therapy were observed from the initial analysis up to 2 years after transfection (Table 5 ). To date, development of tumors or progression of diabetic retinopathy has not been observed in any patient transfected with HGF plasmid DNA during the trial up to 2 years after transfection. No patient had a major amputation during the 2 years, whereas 1 patient (No. 17) had a minor amputation. In addition, 2 patients died because of hyperkalemia after operation at 7 months and pneumonia at 7 months, respectively ( Table 5 ). The committee independent from the investigators evaluated these incidents as not related to HGF gene therapy. The cumulative rates of major amputation and mortality are shown in Table 6 .
Discussion
The present study reported 2-year follow-up study of HGF gene therapy in 22 cases. The initial end points evaluated at 2 months after transfection exhibited a significant improvement in functional end point as assessed by ABI measurement and clinical end points as assessed by VAS and ischemic ulcer. 17 After the initial analysis, we performed the long-term analysis up to 2 years after transfection in this study. The most striking point from the present study is that an improvement in ABI, ulcer size, and rest pain continued up to 2 years after transfection. It is well known that the duration of gene expression driven by naked plasmid DNA is usually not longer than 1 month after injection. Indeed, our preclinical study also confirmed the transient expression of transgene using naked plasmid HGF DNA. 10, 13, 14 Nevertheless, the present study demonstrated that the efficacy of HGF gene therapy was sustained up to 2 years after transfection. Especially, ABI as a functional end point to reflect an improvement in blood flow was significantly increased up to 2 years after transfection. To our knowledge, such an improvement has not previously been achieved spontaneously or with medical therapy in patients with CLI. One of the possible explanations is that the increase in blood vessels induced by HGF at early time point might enlarge the collateral vessels at later time point over the transient expression of exogenous HGF. Alternatively, as exogenous HGF upregulated endogenous HGF and VEGF through an essential transcription factor for angiogenesis, ets-1, 11,21 increase in endogenous HGF and VEGF might work for the continuous growth of collateral formation. Moreover, the lymphangio genetic effects of HGF might contribute the reduction in edematous lesion in Buerger disease. 22 For example, the fingers of case 3 patients were edematous at baseline and 2 months, whereas his edema almost disappeared at 24 months after the therapy (Figure 2, lower) . However, 2 years after transfection, ABI seems to be slightly decreased compared with 6 months. Another treatment using HGF gene might be necessary to develop and maintain the collateral formation, although further studies must be done.
It is more important to consider the clinical application that clinical symptoms, such as rest pain and ischemic ulcer, were gradually decreased in a time-dependent manner. The improvement in these clinical symptoms was different from the time course of ABI. ABI and maximum walking distance peaked at around 3 to 6 months and then decreased a little, whereas rest pain (VAS scale) and ulcer size improved continuously until 2 years after gene therapy. Possible explanation for this discrepancy includes that improvement in blood flow by HGF gene therapy might increase the local flow, resulting in the continuous improvement in resting pain and ulcer size. In patients with CLI, it is well known that critical point to improve resting pain and ulcer would have existed. Probably, the increase in ABI over the critical value 0.5 might lead to the Largest ulcers and all ulcers are indicated as number of healed ulcers/number of ulcers at baseline (%). Complete healing shows the number of patients whose ulcers were completely healed. One patient (case no. 2) with 4 ulcers was excluded at 4 months because of participation for other angiogenic trial and died at 7 months due to hyperkalemia on the day that the patient underwent peripheral artery bypass surgery. 2M, 6M, 12M, and 24M indicate 2, 6, 12, and 24 months, respectively, after the second injection.
continuous improvement in clinical symptoms up to 2 years after gene therapy. In this study, 8 of 9 patients with CLI whose ABI was measurable achieved continuous improvements in rest pain and ulcers at 2 years. The ABI was maintained over 0.5 in 8 of 9 CLIs, although, in 7 of 9 ABI peaked out from 6-12 months to 24 months. It was suggested that in the patients whose ABI was over 0.5, local blood was sufficient to exceed the critical point to improve rest pain and ulcer. However, from this study, it is not clear how long the improvement in clinical symptoms would be continued over 2 years.
It should be noted that 3 randomized placebo-controlled double-blinded studies (1 phase III trial in Japan and 2 phase II trial in the United States) successfully demonstrated the effectiveness of HGF gene therapy. HGF-STAT trial, a phase II randomized placebo-controlled double-blinded study, demonstrated that transcutaneous oxygen tension significantly increased at 6 months in the high-dose HGF group compared with the placebo, low-dose, and middle-dose groups. 19 Additional phase II study in the United States also demonstrated that change in toe brachial pressure index, as well as VAS, had significantly improved from baseline at 6 months in HGF-treated group compared with placebo. 20 More dramatic evidence of the clinical efficacy of HGF gene therapy was obtained from phase III study in Japan. In this study enrolling 44 patients, the overall improvement rate of the primary end point was 70.4% in the HGF group and 30.8% in the placebo group, showing a significant difference. 18 Especially, the HGF group achieved a significantly higher improvement rate (100%) than the placebo group (40%) to reduce ischemic ulcer. 18 Up to 6 months after HGF gene therapy, all clinical studies demonstrated the safety of this treatment. In this study, even up to 2 years after HGF gene therapy, few safety concerns were documented. In this study, 1228 adverse effects based on good clinical practice guideline were reported during the 2 years. However, some of the moderate adverse effects, such as pain or small hemorrhages at the injected sites, were only considered 2M, 6M, 12M, 24M indicate 2, 6, 12, and 24, respectively, months after the second injection. *The number of the cases that improved between baseline and 2 months. †The number of the cases that improved or discontinued between 2 months and 6 months. ‡The number of the cases that discontinued between 6 months and 12 months. §The number of the cases that improved or worsened between 6 months and 12 months. to be related to gene therapy. But most of them were not considered to be related to gene therapy. Potential side effects, such as hemangioma, cancer, or worsening diabetic retinopathy, were not observed during the 2 years after transfection. Indeed, the previous study demonstrated no increase in the serum HGF concentration during gene therapy. 17 More exciting data of the present long-term follow-up study are the incidence of major amputation and mortality. Previous HGF-0205 trial (phase II) documented that complete ulcer healing at 12 months occurred in 31% of patients in the HGF group and 0% in the placebo group. 20 In this study, major amputation of the treated limb with HGF plasmid was 0% through 2-year follow-up, or mortality was 9.5% at 12 months and up to 2 years (Table 6 ). In contrast, historical control studies demonstrated higher amputation and mortality rate. TransAtlantic Inter-Society Consensus-II stated that 1-year natural history of CLI included 30% major amputation and 25% death. 23 Data from control group of other angiogenic gene therapy could represent a natural history of nonrevascularized CLI. For example, phase II fibroblast growth factor gene therapy study showed 33.9% major amputation rate and 23.2% death rate at 1 year in the placebo group, 6 whereas in the phase III fibroblast growth factor gene therapy major amputation was 21% and mortality was 15% at 1 year. 7 However, it was reported that the age-adjusted major amputation rate was lower in Japanese population than in north of England and North America. 24 In Japan, although few reports mentioned the fate of CLI, Shigematsu et al 25 reported 15% major amputation rate and 18.5% mortality at 1 year, and Kumakura et al 26 reported 27.3% death rate at 1 year. Compared with these natural history data of CLI in Japan, in the current study, the rate of amputation-free survival and mortality in patients treated with HGF gene seemed to be favorable.
However, the long-term clinical outcome of angiogenic therapy using bone marrow mononuclear cells implantation reported that the mortality rate at 2 years was 20% and 0% in ASO and TAO group, respectively, whereas the amputation rate at 2 years was 33% and 9% in ASO and TAO, respectively. 27 Although the direct comparison is difficult because of the differences in the patient population, HGF gene therapy seems to be superior to cell therapy in event-free survival. In the cell therapy, ABI was not significantly improved, whereas ulcer size and rest pain (VAS) were reduced, and its effect was sustained up to 2 years. In the present study, HGF gene therapy significantly improved ABI up to 2 years. In the HGF study, baseline ABI (0.46) was lower than that in cell therapy (0.58 in ASO group). These results suggest that HGF gene therapy might be more suitable to treat patients with lower ABI.
This study has several limitations. First, this is not a randomized or placebo-controlled study. Second, this trial was the preliminary study before phase III randomized trial, and the number of involved patients was small. Thus, statistical values might be weak, even if P values were calculable and significant. Third, the long-term results from the present study might be biased because of some unanalyzable dropout patients. During the 2-year follow-up, there were 4 unanalyzable dropout cases: Nos 2, 4, 8, and 14, all of whom were patients with CLI, whereas the remaining group had 7 cases of intermittent claudication and 11 of CLI. The dropout group could have included more severe patients than the remaining group. Thus, it remains possible that more severe patients tend to drop out, and the results from the current study may have potential for bias to be overestimated.
Overall, the present study demonstrated that the 2-year long-term efficacy of phase I/IIa open-label study using intramuscular injection of naked HGF plasmid is safe, feasible, and might achieve successful improvement in ischemic limbs as sole therapy. Larger studies to determine whether HGF plasmid can avoid major amputation and decrease the mortality in patients with CLI are warranted.
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